Amicus Therapeutics, Inc.
Symbol: FOLD
NASDAQ
10.4
USDMarktpreis heute
-20.1432
P/E-Verhältnis
-0.2119
PEG-Verhältnis
3.08B
MRK Kapital
- 0.00%
DIV Rendite
Amicus Therapeutics, Inc. (FOLD) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1099.23 | 286.2 | 293.6 | 482.5 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 217.01 | 39.2 | 144.8 | 237.3 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 292.86 | 87.6 | 66.2 | 52.7 | ||||||||||||||||||||
balance-sheet.row.inventory | 195.02 | 59.7 | 23.8 | 26.8 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 191.73 | 49.5 | 40.2 | 34.8 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 1778.84 | 483.1 | 423.8 | 596.8 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 236.73 | 58 | 60.3 | 63.1 | ||||||||||||||||||||
balance-sheet.row.goodwill | 791.19 | 197.8 | 197.8 | 197.8 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 86.92 | 20.5 | 23 | 23 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 878.11 | 218.3 | 220.8 | 220.8 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | 13.44 | 3.1 | 4.3 | -4.9 | ||||||||||||||||||||
balance-sheet.row.tax-assets | -10.36 | 0 | 4.9 | 4.9 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 75.82 | 15.5 | 10 | 24.4 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 1193.74 | 294.8 | 300.4 | 308.3 | ||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 2972.58 | 777.9 | 724.2 | 905.1 | ||||||||||||||||||||
balance-sheet.row.account-payables | 76.76 | 15.1 | 15.4 | 21.5 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | 31.93 | 8.3 | 8.6 | 7.4 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 12.43 | 12.4 | 5.9 | 6.2 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 1722.72 | 387.9 | 443.6 | 432.7 | ||||||||||||||||||||
Deferred Revenue Non Current | 17.72 | 0 | 4.7 | 7.3 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -17.72 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 513.63 | 131.8 | 110.1 | 117.1 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 1830.25 | 450 | 462.1 | 451.8 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 227.27 | 48.9 | 60.1 | 50.8 | ||||||||||||||||||||
balance-sheet.row.total-liab | 2465.01 | 617.7 | 601.1 | 597.8 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 6.77 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.common-stock | 11.48 | 2.9 | 2.8 | 2.8 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | -10548.38 | -2684.1 | -2532.5 | -2295.9 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -4.04 | 5.3 | -12.1 | 5 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 11041.73 | 2836 | 2664.8 | 2595.5 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 507.56 | 160.2 | 123 | 307.4 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 2972.58 | 777.9 | 724.2 | 905.1 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-equity | 507.56 | 160.2 | 123 | 307.4 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 2972.58 | - | - | - | ||||||||||||||||||||
Total Investments | 220.09 | 42.3 | 144.8 | 237.3 | ||||||||||||||||||||
balance-sheet.row.total-debt | 1803.53 | 445.1 | 452.1 | 440.1 | ||||||||||||||||||||
balance-sheet.row.net-debt | 921.3 | 198.1 | 303.3 | 194.9 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -151.58 | -151.6 | -236.6 | -250.5 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 7.87 | 7.9 | 5.3 | 6.2 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | -9.97 | -4.9 | 0 | 0 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 86.08 | 86.1 | 76.5 | 57.8 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | -40.05 | -48 | -39.9 | -18.6 | |||||||||||||||||||
cash-flows.row.account-receivables | -20.11 | -20.1 | -17.3 | -8.2 | |||||||||||||||||||
cash-flows.row.inventory | -44.61 | -44.6 | -5.3 | -7.8 | |||||||||||||||||||
cash-flows.row.account-payables | 49.19 | 49.2 | -6.4 | 7.4 | |||||||||||||||||||
cash-flows.row.other-working-capital | -24.53 | -32.5 | -10.8 | -10 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | 38.57 | 41.5 | 28 | 2.5 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -69.09 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -7.44 | -7.4 | -3.8 | -3.9 | |||||||||||||||||||
cash-flows.row.acquisitions-net | -12.2 | 0 | 3.4 | 3.9 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | -91.72 | -91.7 | -243.3 | -341.4 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 197.23 | 197.2 | 335.9 | 424 | |||||||||||||||||||
cash-flows.row.other-investing-activites | 12.2 | 0 | 0 | -3.9 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 98.06 | 98.1 | 92.3 | 78.8 | |||||||||||||||||||
cash-flows.row.debt-repayment | -20.96 | -21 | -0.3 | -0.5 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 95.35 | 103.2 | 4.3 | 199.8 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | -17.92 | 0 | -11.5 | -15 | |||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | -4.3 | -15 | |||||||||||||||||||
cash-flows.row.other-financing-activites | 7.19 | -20.6 | 4.3 | 42.8 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 61.68 | 61.7 | -7.5 | 212.1 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 6.31 | 6.3 | -14.6 | -5 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | 96.83 | 98.2 | -96.3 | 83.3 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 892.58 | 247 | 153.1 | 249.5 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 795.75 | 148.8 | 249.5 | 166.2 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | -69.09 | -69.1 | -166.6 | -202.5 | |||||||||||||||||||
cash-flows.row.capital-expenditure | -7.44 | -7.4 | -3.8 | -3.9 | |||||||||||||||||||
cash-flows.row.free-cash-flow | -76.53 | -76.5 | -170.3 | -206.4 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 399.36 | 399.4 | 329.2 | 305.5 | |||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 39.51 | 45.2 | 38.6 | 34.5 | |||||||||||||||||||||
income-statement-row.row.gross-profit | 359.85 | 354.2 | 290.6 | 271 | |||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||||
income-statement-row.row.research-development | 152.38 | - | - | - | |||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||||
income-statement-row.row.other-expenses | -8.69 | -15.9 | 5.3 | 6.2 | |||||||||||||||||||||
income-statement-row.row.operating-expenses | 431.11 | 427.7 | 495.1 | 471 | |||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 470.62 | 472.9 | 533.7 | 505.4 | |||||||||||||||||||||
income-statement-row.row.interest-income | 7.08 | 7.1 | 3 | 0.5 | |||||||||||||||||||||
income-statement-row.row.interest-expense | 24.18 | 50.1 | 37.1 | 32.5 | |||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -63.86 | -76.6 | -37.6 | -41.6 | |||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||||
income-statement-row.row.other-operating-expenses | -8.69 | -15.9 | 5.3 | 6.2 | |||||||||||||||||||||
income-statement-row.row.total-operating-expenses | -63.86 | -76.6 | -37.6 | -41.6 | |||||||||||||||||||||
income-statement-row.row.interest-expense | 24.18 | 50.1 | 37.1 | 32.5 | |||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 4.13 | 7.9 | 12.5 | 3.8 | |||||||||||||||||||||
income-statement-row.row.ebitda-caps | -94.93 | - | - | - | |||||||||||||||||||||
income-statement-row.row.operating-income | -76.96 | -73.5 | -204.4 | -199.9 | |||||||||||||||||||||
income-statement-row.row.income-before-tax | -150.1 | -150.1 | -242 | -241.6 | |||||||||||||||||||||
income-statement-row.row.income-tax-expense | 7.74 | 1.5 | -5.5 | 8.9 | |||||||||||||||||||||
income-statement-row.row.net-income | -151.58 | -151.6 | -236.6 | -250.5 |
Häufig gestellte Frage
Wie hoch ist die Amicus Therapeutics, Inc. (FOLD) Gesamtvermögen?
Amicus Therapeutics, Inc. (FOLD) Gesamtvermögen ist 777880000.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist 218583000.000.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.901.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist -0.261.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist -0.380.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist -0.193.
Was ist der Amicus Therapeutics, Inc. (FOLD) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist -151584000.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 445059000.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 427651000.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 246994000.000.